

<b>A.24</b>	<b>Levetiracetam – epilepsy – EML and EMLc</b>
<b>Draft recommendation</b>	<input checked="" type="checkbox"/> Recommended <input type="checkbox"/> Not recommended <p>Justification: Add levetiracetam to the EML as therapeutic alternatives to Lamotrigine.</p> <p>Monotherapy with lamotrigine or levetiracetam, or valproic acid (sodium valproate), usually considered as first line therapy for generalized-onset seizures and focal-onset seizures in adults and children. Levetiracetam is a cost effective anti-epilepsy medicine. Levetiracetam is generally well tolerated by adults and children.</p>
Does the proposed medicine address a relevant public health need?	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No <input type="checkbox"/> Not applicable <p>Comments:</p>
Does adequate evidence exist for the efficacy/effectiveness of the medicine for the proposed indication?  (this may be evidence included in the application, and/or additional evidence identified during the review process)	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No <input type="checkbox"/> Not applicable <p>Comments:</p>
Does adequate evidence exist for the safety/harms associated with the proposed medicine?  (this may be evidence included in the application, and/or additional evidence identified during the review process)	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No <input type="checkbox"/> Not applicable <p>Comments:</p>
Are there any adverse effects of concern, or that may require special monitoring?	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No <input type="checkbox"/> Not applicable <p>Comments:</p>

24<sup>th</sup> WHO Expert Committee on Selection and Use of Essential Medicines  
Expert review

<p>Are there any special requirements for the safe, effective and appropriate use of the medicines?</p> <p>(e.g. laboratory diagnostic and/or monitoring tests, specialized training for health providers, etc)</p>	<p><input type="checkbox"/> Yes</p> <p><input checked="" type="checkbox"/> No</p> <p><input type="checkbox"/> Not applicable</p> <p>Comments:</p>
<p>Are there any issues regarding cost, cost-effectiveness, affordability and/or access for the medicine in different settings?</p>	<p><input type="checkbox"/> Yes</p> <p><input checked="" type="checkbox"/> No</p> <p><input type="checkbox"/> Not applicable</p> <p>Comments:</p>
<p>Are there any issues regarding the registration of the medicine by national regulatory authorities?</p> <p>(e.g. accelerated approval, lack of regulatory approval, off-label indication)</p>	<p><input type="checkbox"/> Yes</p> <p><input checked="" type="checkbox"/> No</p> <p><input type="checkbox"/> Not applicable</p> <p>Comments:</p>
<p>Is the proposed medicine recommended for use in a current WHO guideline?</p> <p>(refer to: <a href="https://www.who.int/publications/who-guidelines">https://www.who.int/publications/who-guidelines</a>)</p>	<p><input checked="" type="checkbox"/> Yes</p> <p><input type="checkbox"/> No</p> <p><input type="checkbox"/> Not applicable</p> <p>Comments: This medicine is proposed as anti-epilepsy medicine in new draft version of WHO mhGAP guideline.</p>